

Index

- Acid fast bacilli, 8, 70
- Active TB
- description, 3
 - diagnosis, 8,70-72
 - drug-susceptibility determination, 8-9,71-72
 - immune responses, 31-32
 - incidence trends, 3-4
 - infectiousness, 29
 - manifestation, 30
 - positive tuberculin skin tests and, 30
 - risk factors, 30, 58
 - treatment, 72-80
- Advisory Council for the Elimination of **Tuberculosis**, 88
- African Americans. See Black Americans
- Age factors. See Elderly individuals; **Immunocompetent** adults; Infants and young children; Race, ethnicity, age, and sex
- Agency for Health Care Policy and Research, 102-103
- AHCPR. See Agency for Health Care Policy and Research
- Aid to Families with Dependent Children, 105
- AIDS. See *also* HIV infection
- association between TB and AIDS among **IVDUs**, 42
 - BCG** vaccination and, 65
 - clinical and radiographic presentation of TB and, 51
 - clinical course of **TB**, 32
 - epidemiologic association with **TB**, 5-6,4243,48
 - IPT** and, 60
 - treatment of active TB and, 76
 - WHO program, 99
- ALA. See American Lung Association
- Alaska Natives
- case rate, 99
 - child case rate, 38, 99
- American Indians. See Native Americans
- American Lung Association
- DOT recommendation, 19
 - support for international TB control activities, 21-22
 - TB control budget recommendations, 93-94
- American **Thoracic** Society
- BCG** vaccination recommendations, 66-67
 - INH** preventive treatment recommendations, 61
 - National Tuberculosis Training Initiative, 95
 - treatment regimen guidelines, 86
- Americans of Asian or Pacific Islands origin
- case rates, 4, 37
 - child case rate, 38
- Amikacin**, 77
- Antimicrobial treatment. See *also* **INH** preventive treatment; *specific drugs by name*
- infectiousness and, 29
 - mechanism of action, 74-75
- Bacillus **Calmette-Guérin** vaccination. See **BCG** vaccination
- BACTEC™**, 8,71
- BCG** vaccination
- CDC recommendations, 63
 - efficacy trials, 8, 64-65
 - impact on TB incidence, 65-66
 - mechanisms of action, 63
 - safety factors, 65

- Tice strain, 63
- U.S. policy, 8,66-67
- WHO recommendations, 7-8,62-63
- Bellevue Hospital, NY**
 - infection control measures, 55
- Black Americans
 - case rates, 4, 5, 37
- BMRC.** See British Medical Research Council
- British Medical Research Council
 - treatment studies, 73, 77, 78
- Capreomycin,** 10,77
- Case rates. See Epidemiology
- Casual contact
 - tuberculosis infection and, 3, 28
- CDC. See Centers for Disease Control and Prevention
- Cell-mediated immunity, 32
- Centers for Disease Control and Prevention
 - Advisory Council for the Elimination of **Tuberculosis,** 88
 - AIDS incidence and **TB,** 42-43
 - BCG vaccination recommendations, 63,66-67
 - costs and effectiveness of treatment, 102-103
 - directly observed treatment, 12, 89
 - drug costs, 10, 11,20,79-80
 - drug shortages, 78
 - failure to implement TB control recommendations, 2
 - formation of State and local TB elimination advisory committees, 97
 - funding increase allocation, 96
 - infection control guidelines, 6-7, 52-54
 - INH** preventive treatment, 58,61,62
 - institutional screening for **TB,** 58
 - MDR-TB** surveys, 6,4446
 - National Action Plan to Combat **Multidrug-Resistant Tuberculosis,** 14,22,23,67, 83, 86, 95-97,98
 - National TB Action Plan, 83
 - National Tuberculosis Training Initiative, 95
 - prescribing practices of physicians in private practice, 86
 - RVCT** surveillance system, 33-34, 82,84
 - skin testing for health care workers, 50
 - spending for **TB,** by function, 94
 - Strategic Plan for the Elimination of **Tuberculosis** in the United States, 12, 86, 94-95
 - TB** control budget, 12, 13, 14,92-94
 - TB** control law survey, 85
 - treatment regimen guidelines, 86
 - treatment regimen studies, 73-74
- Centers of excellence for patients with **TB,** 23-24,94
- Chest x-rays, 8,20,70
- Chicago
 - Cook County Hospital infection control measures, 56
 - epidemiology of TB report, 84
- Children. See Infants and young children
- Cities. See *also* **Chicago; New York City**
 - direct Federal intervention, 18-19
 - TB case rates, 35-37
- Clofazimine,** 77
- CMI. See Cell-mediated immunity
- Completion of treatment
 - consequences of treatment failure, 82
 - directly observed treatment and, 89-90
 - HIV-infected individuals, 76,77
 - INH** preventive treatment, 58-59
 - MDR-TB** and, 77
 - outcome data, 10, 82-84
 - patient behavior and, 10-11, 87
- Cook County Hospital, Chicago
 - infection control measures, 56
- Core Curriculum on **Tuberculosis,** 95
- Correctional institutions. See *also* Prisoners and inmates
 - Federal prison system, 99
 - MDR-TB** outbreaks, 6,41
 - prevalence of **TB,** 40
- Cough-inducing medical procedures
 - health care worker exposure and, 50
 - infectiousness factor, 29, 52
- Crack cocaine use
 - TB and, 41
- Culture examination methods of diagnosis, 8,71
- Cycloserine, 10,77
- Delayed-type hypersensitivity, 32,59-60
- Delivery of treatment. See *also* Completion of treatment; Treatment of active TB
 - outcome data, 82-84
 - social factors, 82, 87
 - strategies for improvement, 88-90
 - treatment outcome factors, 84-87
- Demographic changes
 - geographic distribution, 4, 35-37

- high-risk populations, 5,40-42
- race, **ethnicity**, age, **and** sex, 4-5, 37-40
- shift to narrower populations, 34-35
- Developing countries
 - AIDS impact on **TB**, 43
 - IPT use, 58
 - MDR-TB** and, 44
 - TB** control policy option, 22
- DI. See Social Security Disability Insurance
- Diagnosis of active **TB**
 - basis for, 8, 70
 - chest x-rays, 8, 70
 - culture examination, 8, 71
 - delayed diagnosis and **MDR-TB** outbreaks, 8,71-72
 - deoxyribonucleic acid method, 9,71
 - necessity for rapid diagnosis, 8, 70, 72
 - sputum smear, 8, 70
- Directly observed treatment, 12,22, 88-90,93, 105, 106
 - policy option, 19
- Disability insurance, See Social Security Disability Insurance
- DNA. See **TB** diagnosis and, 9,71
- DOT. See Directly observed treatment
- Droplet nuclei, 30
- Drug shortages, 78
- Drug-susceptibility testing, 8-9,71-72
- Drug users, See Intravenous drug users
- DTH. See Delayed-type hypersensitivity
- Elderly individuals
 - case rate, 4, 40, 41
 - hepatitis side effect to treatment, 75
- Epidemiology
 - case rates by locality, 4, 35-37
 - case rates by race, **ethnicity**, age, and sex, 37-40
 - case rates for high-risk populations, 40-42
 - demographic changes, 4-6,3442
 - HIV and AIDS, 42-44
 - incidence trends, 33-34
 - multidrug-resistant TB**, 44-47
 - resurgence factors, 1, 47-48
- Ethambutol, 9,73,75,76,79, 80
- Ethionamide, 10,77
- Ethnicity**. See Race, **ethnicity**, age, and sex
- Etiology of tuberculosis, 27
- Extrapulmonary **TB**
 - AIDS and, 43
 - description, 3, 31
 - HIV infection and, 76
- FDA. See Food and Drug Administration
- Federal Bureau of Prisons
 - TB** control activities, 12-14,20,99
- Federal Government involvement in **TB** control. See *also specific agencies and programs by name*
 - health services research, 102-103
 - housing, 103
 - public health activities, 92-100
 - regulation of technologies, 15, 102
 - reimbursement for **TB** services, 103-106
 - research and development, 14-15, 100-102
- Federal health insurance programs
 - Medicaid, 15-16,25-26, 104-105
 - Medicare, 15-16, 106
- Fluoroquinolones**, 78
- Food and Drug Administration
 - BCG** vaccination approval, 63
 - drug development, 23
 - drug shortages, 10,78
 - new drug approval, 78
 - TB** control activities, 102
- Foreign-born individuals. See Immigrants and refugees
- Gender factors. See Race, **ethnicity**, age, and sex
- Gene probes, 71
- Geographic distribution
 - case rates, 35-37
- Hansen Disease Center, Carville, LA, 100
- HCFA. See Health Care Financing Administration
- HCWs. See Health care workers
- Health Care Financing Administration
 - Medicaid regulation, 16, 105
 - Medicare funding, 106
- Health care workers. See *also* Primary care physicians
 - annual screening, 50
 - BCG** vaccination recommendations, 66
 - directly observed treatment and, 12, 88-89,90
 - HIV-infected, 50-51
 - job-specific infection rates, 50
 - MDR-TB** exposure, 50
 - MDR-TB** infectiousness and, 29
 - National Tuberculosis Training Initiative and, 95
 - powered air purification respirators and, 54

144 | The Continuing Challenge of Tuberculosis

- risk of **tuberculosis** infection, 3, 29
- Health Resources and Services Administration
 - TB control activities, 14, 100
- Hepatitis
 - drug side effect, 75
 - INH** preventive treatment and, 61-62
- High-risk populations, **40-42**. See *also specific groups by name*
- Hispanic Americans
 - case rates, 4-5, 37
 - child case rate, 38
- History of **TB**, 2-3, 27
- HIV infection. See *also AIDS*
 - active **TB**, development of, 30
 - BCG** vaccination and, 63, 64, 65, 66-67
 - chest x-rays findings and, 70
 - clinical course of **TB**, 27, 32
 - completion of TB treatment and, 76, 77
 - DTH and **CMI** impairment, 32
 - epidemiologic association with **TB**, 5-6, 42, 43
 - extrapulmonary TB** and, 31
 - infectiousness and, 29-30
 - INH** preventive treatment and, 56, 58, 61
 - MDR-TB** and, 42
 - nontuberculous mycobacterial** infections and, 70
 - risk factor for **TB**, 55
 - TB manifestation, 32
 - tuberculin skin testing and, 60
- Homeless individuals
 - case rate, 5, 40, 48
 - IPT** for, 58
- Hospitals
 - MDR-TB** outbreaks, 6, 46, 50
 - Medicare reimbursement, 106
 - VA hospital infection control guidelines, 98
- HRSA. See Health Resources and Services Administration
- IHS**. See Indian Health Service
- Immigrants and refugees
 - case rate, 5, 40, 48
 - child case rate, 39
 - INS TB screening** activities, 98
 - MDR-TB** and, 44
 - tuberculin skin testing, 60
- Immigration and **Naturalization** Service
 - TB control activities, 14, 98
- Immune responses
 - description, 31-32
 - development of active TB and, 30
- Immunocompetent** adults
 - chest x-rays findings of **TB**, 70
 - development of active **TB**, 30
- Implantable** devices for TB treatment, 10, 78, 102
- Incidence trends, 33-34
- Indian Health Service
 - TB control activities, 14, 99
- Infants and young children
 - acquiring active TB after **tuberculosis** infection, 28
 - BCG** vaccination, 8, 66
 - case rates, 5, 38-39, 99
 - clinical course of **TB**, 27, 32
 - diagnosis of active **TB**, 71
 - prevalence of **TB**, 56
 - treatment of active **TB**, 75
- Infection control
 - CDC** guidelines, 6-7, 52-54
 - combining interventions, 54
 - MDR-TB** outbreaks, 50-52, 72
 - personal protection devices, 54
 - respiratory isolation, 51, 53
 - W radiation, 53-54
 - ventilation systems, 51, 53
 - veterans hospital guidelines, 98
- Infectiousness
 - concentration of infectious particles in the air, 30
 - factors, 3
 - MDR-TB**, 29
 - tuberculosis** infection, 29
- INH**. See **Isoniazid**
- INH** preventive treatment. See *also Isoniazid*;
 - Treatment of active TB
 - adverse effects, 61-62
 - completion problems, 58-59
 - efficacy in TB prevention, 7, 55, 61
 - policy option, 20
 - purpose, 61
 - selective use policy, 56, 58-59
- Inmates. See Prisoners and inmates
- INS**. See Immigration and Naturalization Service
- Institutional settings. See *also* Correctional institutions; Hospitals; Nursing homes
 - MDR-TB** outbreaks, 6, 46, 50-52
- Intravenous drug users
 - association between TB and AIDS, 42
 - case rate, 5, 40

- HIV infection and, 43
- Isoniazid, 9,73-80. See *also* INH preventive treatment
 - MDR-TB and, 44
 - side effects, 7
- IVDUs. See Intravenous drug users
- Kanamycin, 10, 77
- Koch, Robert, 2, 27
- Laryngeal TB, 29,31
- Latent TB. See Tuberculous infection
- Long-term care facilities
 - TB risk, 40
- Louisiana
 - Hansen Disease Center, 100
- MDR-TB. See Multidrug-resistant TB
- Medicaid
 - eligibility and benefits for TB patients, 104-105
 - policy options, 25-26
 - reimbursement for DOT, 105
- Medicare, 106
- Migrant farm workers
 - case rate, 5, 41-42
- Mortality rates
 - AIDS and, 43
 - before antibiotic treatment, 72
 - MDR-TB outbreaks in institutions, 46
- Multidrug-resistant TB
 - categories of resistance, 44
 - completion of treatment and, 77
 - correctional institution outbreak, 6, 41
 - delayed diagnosis and, 71-72
 - epidemiology, 44-47
 - infectiousness, 29
 - institutional outbreaks, 6, 41, 46-47, 50-52
 - intravenous drug use and, 40
 - risk factors, 72
 - second-line drugs, 77
 - transmission, 44, 46-47
 - treatment, 76-78
- Mycobacterium avium*
 - AIDS patients and, 43
- Mycobacterium bovis*. See BCG vaccination
- Mycobacterium tuberculosis*, 2, 27
 - subpopulation characteristics, 74-75
- National Action Plan to Combat Multidrug-Resistant Tuberculosis, 14,23,67, 86, 95-97, 98, 101
- National Center for Nursing Research, 101
- National Center for Research Resources, 101
- National Heart, Lung, and Blood Institute, 101
- National Institute for Environmental Health Sciences, 101
- National Institute for General Medical Sciences, 101
- National Institute for Occupational Safety and Health
 - occupational risks from respiratory exposures to TB, 97
 - powered air purification respirators, 7, 54
- National Institute of Allergy and Infectious Diseases
 - IPT efficacy trials, 61
 - TB research activities, 101
 - vaccine development efforts, 67
- National Institute of Mental Health, 101
- National Institute on Drug Abuse, 101
- National Institutes of Health
 - TB Prevention and Control Research Units, 101
 - TB research, 100-102, 103
- National TB Action Plan, 83
- National Tuberculosis Training Initiative, 95
- National Vaccine Program Office
 - TB research, 100
- Native Americans
 - case rates, 37, 99
 - child case rate, 38, 99
- New York City
 - Bellevue Hospital infection control measures, 55
 - case rate, 4, 35-36, 48
 - homeless population cases, 5,40
 - intravenous drug use and MDR-TB association, 40-41
 - MDR-TB case rate, 6,46
 - MDR-TB incidence, 72
 - MDR-TB transmission, 44
 - Rikers Island Correctional System infection control measures, 57
 - TB among HIV-infected persons, 30
 - TB control services, 85-86
 - treatment completion trials, 83-84
- New York State
 - Medicaid funding for DOT, 105
 - prison system prevalence, 41
- NIAID. See National Institute of Allergy and Infectious Diseases

- NIOSH.** See National Institute for Occupational Safety and Health
- Non-Hispanic white Americans**
 case rates, 37
 child case rate, 38
- Nonadherence.** See Completion of treatment
- Noncompliance.** See Completion of treatment
- Nontuberculous mycobacteria.** See *also* **Mycobacterium avium**
 AIDS patients and, 43
 sputum smear and, 70
- North Carolina**
 migrant farm worker survey, 42
- Nursing homes**
 TB risk, 40
- Occupational Health and Safety Administration**
 responsibilities, 97
 TB-related activities, 14,97-98
- OSHA.** See Occupational Health and Safety Administration
- PAPRs.** See Powered air purification respirators
- Para-aminosalicylic acid,** 10,73,76,77,78, 79,80, 102
- Particulate respirators,** 7,54
- PAS.** See **Para-aminosalicylic acid**
- Personal protection devices**
 infection control measure, 54
- Phenazines,** 78
- PHS.** See U.S. Public Health Service
- Physicians.** See Primary care physicians
- Policy options**
 categories, 16
 description, 16-26
 financial issues, 24-26
 public health infrastructure, 16-22
 research and development, 22-24
- Polymerase chain reaction,** 9, 71
- Powered air purification respirators,** 7,54
- Prevention strategies**
 BCG vaccination, 62-67
 infection control, 50-54
 INH preventive treatment, 55,56,58-59,61-62
 tuberculin skin testing, 55-56, 59-61
- Primary care physicians**
 National Tuberculosis Training Initiative and, 95
 patient monitoring, 11-12, 86-87
 prescribing errors, 86
- Prisoners and inmates.** See *also* Correctional institutions
 case rate, 5, 41, 48
 MDR-TB outbreaks, 6,46
- Pulmonary TB**
 BCG vaccination efficacy, 66
 description, 3, 30
- Pyrazinamide**
 active TB treatment, 9, 73-80
 efficacy in TB prevention, 61
- PZA.** See **Pyrazinamide**
- Quinolones,** 77
- Race, ethnicity, age, and sex**
 case rates, 4-5, 37-40
- Refugees.** See Immigrants and refugees
- Reimbursement for TB services**
 Federal health insurance programs, 103-106
 Social Security programs, 103
- Report of a Verified Case of Tuberculosis,** 33-34, 82, 84
- Research and development**
 National Institutes of Health, 14, 100-102
 National Vaccine Program Office, 100
 Substance Abuse and Mental Health Services Administration, 14, 100
- Respiratory isolation,** 51, 53
- RIF.** See Rifampin
- Rifamate™,** 10,73,78,79, 80, 88
- Rifampin**
 active TB treatment, 9, 73-80
 efficacy in TB prevention, 61
 MDR-TB and, 44
- Rifamycin,** 78
- Rifater™,** 10,73,78,79,80, 88
- Rikers Island, NY, Correctional System**
 infection control measures, 57
- RVCT.** See Report of a Verified Case of Tuberculosis
- Ryan White Comprehensive AIDS Resources**
 Emergency Act, 100
- Screening tests.** See **Tuberculin** skin testing
- Sex.** See Race, ethnicity, age, and sex
- Skin testing.** See Tuberculin skin testing
- SM.** See Streptomycin
- Social Security Disability Insurance,** 15,24, 103

- Sputum smear, 8,70
- SSI, See Supplemental Security Income program
- State and local TB control programs
 - outpatient medical care, 104
 - State TB laws, 11, 84-85
 - TB elimination advisory committees, 97
 - universal purchase of anti-TB drugs, 20, 21
- Strategic Plan for the Elimination of Tuberculosis in the United States, 12, 86, 94-95
- Streptomycin, 9,72-73,75,76,78,79, 80, 102
- Substance Abuse and Mental Health Services Administration
 - TB research, 14, 100
- Supplemental Security Income program, 15,24, 103
- Surgical intervention, 10,72,77

- TB control services
 - description, 85
 - program problems, 85
 - State TB laws, 84-85
- TB Prevention and Control Research Units, 101
- Tice strain of BCG vaccine, 63
- Transmission
 - active tuberculosis, 30
 - MDR-TB, 44,46-47
 - stages of TB, 28
 - tuberculous infection, 28-30
- Treatment failure. See Completion of treatment
- Treatment of active TB
 - alternative methods of drug delivery, 10, 78
 - antimicrobial treatment rationale, 74-75
 - bactericidal phase, 9, 75
 - combined-drug regimens, 9, 72-74, 75, 76-77, 78
 - completion of treatment, 10, 11, 58-59, 76, 77, 82-84, 89-90
 - current regimens, 9, 73, 75
 - drug costs, 10, 11,79-80
 - drug shortages, 10, 78
 - duration, 9-10, 73,75,76,77
 - first-line drugs, 9,73
 - implantable devices, 10, 78, 102
 - individuals with AIDS and, 76
 - introduction of antibiotic treatment, **9, 72-73**
 - multidrug-resistant TB, 9-10, 76-78
 - new approaches, 10, 78
 - second-line drugs, 10, 73, 77, 79, 80
 - sterilizing phase, 9, 75
 - surgical intervention, 10, 72, 77
- Treatment outcome factors
 - clinic management, 85
 - data, 82-84
 - medical care practices, 86-87
 - patient behavior, 87
 - TB control services and, 84-86
- Tubercle bacilli. See *Mycobacterium tuberculosis*
- Tuberculin skin testing
 - accuracy, 7, 30, 60
 - description, 3
 - false negative reading, 70
 - false positive reading, 60
 - high-risk groups, 55-56
 - limitations, 60-61
 - mechanism, 59-60
 - policy option, 20
 - positive reading, 30
 - result interpretation, 60
 - “worried well” persons and, 28
- Tuberculous infection
 - description, 3
 - host factors, 30
 - probability of acquiring active TB and, 28
 - risk factors, 28-30, 58
 - transmission, 28

- Ultraviolet radiation
 - inactivation of droplet nuclei, 30
 - infection control measure, 7, 53-54
- United Hospital Fund
 - directly observed treatment recommendation, 89
- U.S. Agency for International Development
 - TB control budget, 14,99
- U.S. AID. See U.S. Agency for International Development
- U.S. Department of Health and Human Services. See *also specific agencies and programs by name*
 - Agency for Health Care Policy and Research, 102-103
 - Core Curriculum on Tuberculosis, 95
 - TB control budget, 14,93
- U.S. Department of Housing and Urban Development, 103
- U.S. Department of Justice
 - TB control activities, 14, 98
- U.S. Department of Veterans Affairs
 - purchase_of drugs in bulk, 21
 - TB control activities, 14, 20, 98

- TB screening, 20
- U.S. **DHHS**. See U.S. Department of Health and Human Services
- U.S. DVA. See U.S. Department of Veterans Affairs
- U.S. Public Health Service. See *also specific agencies and programs by name*
 - history of TB prevention and control, 92-93,94
 - National Action Plan, 101
 - reporting system for TB, **3-4**, 33
 - treatment completion trials, 83
- UV radiation. See Ultraviolet radiation
- Ventilation systems, 51, 53
- Washington Post* editorial, 28
- WHO. See World Health Organization
- World Health Organization
 - AIDS impact on T13 in developing countries, 43
 - BCG vaccination recommendations, 62-63
 - Global Program on AIDS funding from U.S. AID, **99**